BARRX Medical, Inc., a Sunnyvale, CA-based company that develops endoscopic treatment solutions for treating precancerous lesions of the esophagus (Barrett’s esophagus) as well as other chronic gastrointestinal diseases, has closed a $15m Series D financing.
The round was led by new investor Highland Capital Partners, with participation from existing investors Delphi Ventures, Alloy Ventures, Frazier Healthcare Ventures, Sutter Hill Ventures, Greenspring Associates and others.
In conjunction with the funding, Bijan Salehizadeh, M.D. from Highland, joins the company’s Board of Directors.
BARRX’s HALO system is becoming a standard of care for treating Barrett’s esophagus and this latest funding will be used to expand the utilization of the technology into new disease states and into new international markets such as Latin America and Asia.
The proprietary bipolar radiofrequency HALO technology has shown encouraging results for the treatment of another precancerous condition of the esophagus (squamous neoplasia) and bleeding disorders of the stomach and rectum.